NG-641

BIOLOGICAL2 trials

Sponsors

Akamis Bio

Conditions

Epithelial TumorMetastatic CancerSquamous Cell Carcinoma of the Head and Neck

Phase 1

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

CompletedNCT04053283

Akamis BioEpithelial Tumor, Metastatic Cancer

Start: 2020-01-23End: 2023-12-20Updated: 2025-03-24

A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck

CompletedNCT04830592

Akamis BioSquamous Cell Carcinoma of the Head and Neck

Start: 2021-11-04End: 2024-10-04Updated: 2025-03-24

Related Papers

A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.

2023-03-106 citations

762 First-in-human phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR)

Regular and Young Investigator Award Abstracts2022-11-019 citations

Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA)

Cancer Research2022-06-154 citations

NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.

Journal of Clinical Oncology2022-06-013 citations

Safety and tolerability of T-SIGn vectors when administered using “flat” versus “low-high-high” (LHH) dosing regimens.

Journal of Clinical Oncology2022-06-01

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

Journal for ImmunoTherapy of Cancer2021-12-0147 citations

437 A multicentre phase 1b study of NG-641, a novel transgene-armed and tumour-selective adenoviral vector, and pembrolizumab as neoadjuvant treatment for squamous cell carcinoma of the head and neck

Regular and Young Investigator Award Abstracts2021-11-014 citations

342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study

Regular and Young Investigator Award Abstracts2021-11-012 citations